Acne scar treatment minimizing downtime and risks: combination of subcision, needle free jet injectors, and CO2 microsubcision devices
Objectives: This session aims to introduce less invasive techniques—specifically, a needle-free jet injector and a CO₂ gas-assisted microsubcision device—for the treatment of atrophic acne scars, with a focus on minimizing complications such as post-inflammatory hyperpigmentation, particularly in patients with skin of color.
Introduction: Patients with darker skin types are at higher risk for post-inflammatory hyperpigmentation (PIH) or hypopigmentation following conventional acne scar treatments like laser resurfacing. There is a growing need for alternative, less invasive methods that effectively improve atrophic acne scars while reducing the risk of pigmentary complications.
Materials / method: We have treated thousands of patients with atrophic acne scars using a combination of minimally invasive approaches: Curejet (needle-free jet injector), Trifill Pro (CO₂ gas-assisted microsubcision device), and manual subcision with cannulas. A review of clinical charts and before-and-after photographs was conducted to evaluate treatment efficacy and safety across varying scar types.
Results: The needle-free jet injector demonstrated significant efficacy in treating icepick, boxcar, and smaller rolling scars. The CO₂ gas-assisted microsubcision device was particularly effective for shallow rolling scars. Deep rolling scars responded best to manual subcision. When used in combination, these three modalities offered comprehensive improvement in atrophic acne scars with minimal downtime and a lower incidence of post-procedural erythema and pigmentary changes compared to laser resurfacing or TCA CROSS.
Conclusion: The integration of needle-free jet injection and CO₂ gas-assisted microsubcision with traditional subcision offers a safe, effective, and minimally invasive treatment strategy for atrophic acne scars—especially in skin of color patients. This combination approach reduces the risk of post-inflammatory pigmentary complications while achieving meaningful clinical improvement.